

THC Form 7
MONTHLY PROGRESS REPORT
February 2018

Name of CSE Issuer	THC BioMed Intl Ltd.
Trading Symbol:	THC
Number of Outstanding Listed Securities	114,580,190 common shares and 17,210,253 reserved for Issuance
Date:	March 5, 2018

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Over the course of the last month, the Issuer continued to focus on expansion of its products and facilities. The Issuer announced intentions to export its products to Europe and other markets.

The Issuer pursued an opportunity, previously announced on December 20, 2017, and entered into a letter of intent to purchase a Farm and Greenhouses on approximately eight and a half acres in the Niagara region, in the Province of Ontario, as described in the Issuer's February 15th news release. The announcement also included that one of the Vendors of the property has agreed to stay on as a consultant, bringing his 32 years expertise as a farmer in this region to bear for Issuer's crops. The Vendor intends to rent a farmhouse located on the property from the Issuer at market rates.

On February 22, 2018, the Issuer was recognized for meeting the requirements of GOOD MANUFACTURING PRACTICE under the Codex Alimentarius Commission, Recommended International Code of Practices, General Principles of Food Hygiene, CAC/RCP 1-1969, Rev. 4 (2003) for the production of Marijuana Plants, dried Marijuana (Propagation, Growing, Harvesting, Drying, Curing and Packaging).

2. Provide a general overview and discussion of the activities of management.
See Item 1.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

On February 15, 2018, the Issuer entered into a letter of intent to purchase a farm and greenhouses on approximately eight and a half acres in the Niagara region, Ontario for the licensed production of cannabis. The new property has approximately seven acres of growing space, including seventy thousand square feet in the greenhouses. Irrigation equipment and all equipment and supplies necessary for the operation of the greenhouses are included in the purchase.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

See Item 3.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

See Item 1.

8. Describe the acquisition of new customers or loss of customers.

The Issuer has continued to register new patients.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

None, except in the ordinary course of business.

11. Report on any labor disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

On February 6, 2018, the Issuer issued 20,000 common shares at a price of \$0.385 per common share pursuant to an option exercise, for gross proceeds of \$7,700. The proceeds from this exercise will be used for general working capital.

On February 8, 2018, the Issuer issued 1,002,673 units at a price of \$1.328 per unit pursuant to a previously announced investment agreement, for gross proceeds of \$1,331,551. Each unit is comprised of one common share and one common share purchase warrant which entitles the warrant holder to purchase one common share of the Issuer for a period of 36 months from the issue date at a price of \$2.08 per share. The proceeds of this private placement will be used for potential expansion of Issuer internationally and within Canada as well as general working capital.

On February 22, 2018, the Issuer issued 15,000 common shares at a price of \$0.385 per common share pursuant to an option exercise, for gross proceeds of \$5,775. The proceeds from this exercise will be used for general working capital.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The former MMPR has been replaced by the new Access to Cannabis for Medical Purposes Regulations (the "ACMPR"). On December 19, 2016, Health Canada amended the Issuer's license to allow the sale of "starting materials" or marijuana plants immediately to legally authorized patients under the ACMPR.

The Issuer's business involves certain risks and uncertainties that are inherent to the Company's industry. For disclosure on risks related to an investment in the Issuer, please refer to the Company's most recent Management's Discussion and Analysis under the titles "Financial Instruments and Risk Management" and "Other Risks and Uncertainties", which is available on SEDAR at www.sedar.com.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **March 5, 2018**

John Miller

Name of Director or Senior Officer

/s/ "John Miller"

Signature

President and CEO

Official Capacity

Issuer Details		
Name of Issuer: THC BioMed Intl Ltd.	For Month End February 2018	Date of Report: YYYYMMDD 2018/03/05
Issuer Address: P.O. Box 20033 Towne Centre		
City/Province/Postal Code: Kelowna, BC V1Y 9H2	Issuer Fax No.: N/A	Issuer Telephone No. 250.870.2512
Contact Name: John Miller	Contact Position: President & CEO	Contact Telephone No. 250.870.2512
Contact Email Address: info@thcbiomed.com	Web Site Address: www.thcbiomed.com	